Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADXS

ADXS - Advaxis Inc Stock Price, Fair Value and News

0.85USD-0.12 (-12.37%)Market Closed
Watchlist

Market Summary

USD0.85-0.12
Market Closed
-12.37%

ADXS Stock Price

View Fullscreen

ADXS RSI Chart

ADXS Valuation

Market Cap

9.1M

Price/Earnings (Trailing)

-0.56

Price/Sales (Trailing)

28.81

EV/EBITDA

-0.56

Price/Free Cashflow

-0.47

ADXS Price/Sales (Trailing)

ADXS Profitability

Operating Margin

-1302.40%

EBT Margin

-5163.40%

Return on Equity

-7.74%

Return on Assets

-184.27%

Free Cashflow Yield

-212.24%

ADXS Fundamentals

ADXS Revenue

Revenue (TTM)

250.0K

ADXS Earnings

Earnings (TTM)

-12.9M

Breaking Down ADXS Revenue

Last 7 days

-36.5%

Last 30 days

28.1%

Last 90 days

-13.1%

How does ADXS drawdown profile look like?

ADXS Financial Health

Current Ratio

0.53

Debt/Equity

0.01

Debt/Cashflow

-7.39

ADXS Investor Care

Shares Dilution (1Y)

492.08%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20223.0M2.4M1.3M250.0K
20213.7M3.8M3.8M3.2M
202015.7M10.6M5.4M253.0K
201912.0M15.0M17.9M20.9M
201810.3M8.6M6.7M6.1M
20177.5M11.0M14.0M12.0M
20160004.0M
20150000
20140001.0M
20130000
20120000
20110000
2010149.4K269.1K388.8K508.5K
200900029.7K

Tracking the Latest Insider Buys and Sells of Advaxis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 07, 2024
israel biotech fund i, l.p.
acquired
11,138,900
0.4
27,847,200
-
Feb 07, 2024
israel biotech fund i, l.p.
sold (taxes)
-6,599,580
1.2465
-5,294,490
-
Oct 18, 2023
amoon growth fund limited partnership
sold
-
-
-
-
Oct 18, 2023
israel biotech fund i, l.p.
bought
-
-
1,317,720
-
Jan 19, 2023
sidransky david
acquired
-
-
46.00
-
Mar 13, 2020
appel roni
sold
-1,320
0.55
-2,401
-
Mar 12, 2020
appel roni
sold
-116
0.58
-200
-
Mar 11, 2020
appel roni
sold
-267
0.67
-399
-
Apr 11, 2019
henderson molly
acquired
9,199
3.6799
2,500
executive vice president & cfo
Apr 11, 2019
gutierrez andres
acquired
13,928
3.7142
3,750
executive vice president & cmo

1–10 of 13

Are Funds Buying or Selling ADXS?

Are funds buying ADXS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADXS
No. of Funds

Unveiling Advaxis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
redmile group, llc
1.9%
211,014
SC 13G/A
Feb 12, 2024
schindel yair chaim
1.31%
560,602
SC 13G/A
Feb 12, 2024
israel biotech fund i, l.p.
40.94%
20,661,639
SC 13D/A
Nov 21, 2023
israel biotech fund i, l.p.
68.6%
23,180,561
SC 13D/A
Oct 31, 2023
israel biotech fund i, l.p.
20.9%
2,584,909
SC 13D/A
Oct 23, 2023
schindel yair chaim
5.21%
560,602
SC 13G/A
Sep 11, 2023
israel biotech fund i, l.p.
31.3%
1,925,601
SC 13D
Feb 08, 2023
redmile group, llc
6.8%
332,353
SC 13G
Jan 30, 2023
schindel yair chaim
12.20%
560,602
SC 13G
Feb 16, 2021
cvi investments, inc.
2.1%
2e+06
SC 13G/A

Recent SEC filings of Advaxis Inc

View All Filings
Date Filed Form Type Document
Feb 20, 2024
PREM14C
PREM14C
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13D/A
13D - Major Acquisition
Feb 12, 2024
4
Insider Trading
Feb 09, 2024
8-K
Current Report
Feb 06, 2024
8-K
Current Report
Jan 03, 2024
8-K/A
Current Report
Nov 21, 2023
SC 13D/A
13D - Major Acquisition
Nov 21, 2023
4
Insider Trading

Peers (Alternatives to Advaxis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Advaxis Inc News

Latest updates
GlobeNewswire13 months ago
InvestorsObserver3 years ago

Advaxis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12023Q12022Q42022Q32022Q32022Q22022Q22022Q12021Q42021Q42021Q32021Q32021Q22021Q12020Q42020Q42020Q32020Q22020Q1
Revenue-100.0%-9,00029,50050,00070,50091,00064,50038,000250,000458,000696,500935,000625,000250,0001,375,0001,615,000807,500-250500750
Cost Of Revenue------91,000----1,146,000-625,000--------
Gross Profit----------90,000-----------
Operating Expenses-----4,853,000-7,291,000-3,252,000--4,371,500-4,381,0007,696,0005,578,000-6,400,0005,842,0006,571,0007,889,000
  S&GA Expenses-47.6%1,448,0002,763,0004,604,000-1,495,0002,881,0002,053,0002,272,0001,768,0002,433,000-3,831,5002,198,0002,678,0003,352,0003,008,000-3,027,0002,384,0002,649,0003,030,000
  R&D Expenses-0.7%5,683,0005,723,0007,265,000--10,031,0007,199,0002,233,0005,580,0001,484,0007,503,000--7,352,5007,368,0001,703,0004,344,0002,570,000-3,373,0003,458,0003,922,0004,859,000
EBITDA Margin0%-51.40-51.40-51.40-51.40-51.40-34.31-20.13-10.80-16.24-13.26-11.21-3.65-5.60-7.72-------
Income Taxes-48.8%65,000127,000-4,207,000--459,000106,000-383,500214,00050,000189,000--527,000167,000-50,000----100,000-50,000-
Earnings Before Taxes15.1%-7,274,000-8,572,000-11,568,000-12,027,500-10,079,000-6,963,000-7,894,000-2,390,000-9,764,000-6,012,000-9,629,000-3,284,000-5,107,000-3,977,000--6,460,000-5,829,000-6,273,000-7,857,000
EBT Margin0%-51.63-51.63-51.63-51.63-51.63-34.47-20.23-10.87-16.31-13.32-11.26-3.77-5.69-7.77-------
Net Income15.6%-7,339,000-8,699,000-7,361,000-12,392,000-10,185,000-6,963,000-8,108,000-2,440,000-9,953,000-6,359,000-9,796,000-3,334,000-5,107,000-3,977,000--6,460,000-5,829,000-6,323,000-7,857,000
Net Income Margin0%-51.46-51.46-51.46-51.46-51.46-34.94-20.57-11.11-16.63-13.58-11.48-3.73-5.75-7.88-------
Free Cashflow18.5%-6,981,000-8,561,000-6,741,00011,058,00011,058,0004,700,0004,700,0001,528,0001,528,000-9,984,00015,125,00015,125,000-2,803,000-2,803,000-------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q42022Q32022Q32022Q22022Q12021Q42021Q42021Q32021Q22021Q12020Q42020Q42020Q32020Q22020Q12019Q42019Q3
Assets-42.5%6,98112,15120,9957,76925,93014,26030,10137,51846,49841,12746,78051,02255,77145,94745,82838,52640,01945,21051,34845,25756,133
  Current Assets-52.4%4,5529,55618,2613,18825,75913,03229,81734,17743,11639,74043,25747,44252,11335,52844,24027,85127,29931,76837,15336,14945,493
    Cash Equivalents-70.0%2,1237,07916,8392,40825,20011,19528,15032,10036,48036,98241,61445,30048,11033,31842,02525,17823,84628,21734,15632,36341,755
  Net PPE-4.2%84588295096038.0099973.0084.001001,1201182783332,1891,2832,3933,6673,8934,1214,3505,592
Liabilities-----2,303-1,9062,3673,724-7,8926,7458,2208,372-8,3468,5539,7739,8005,7266,864
  Current Liabilities1.2%8,5278,4279,8336,2132,3035,7051,9062,3673,7196,4727,8806,7458,2203,5776,8773,2913,2494,2254,0124,5215,670
  Long Term Debt-2,068--------------------
    LT Debt, Non Current-2,068--------------------
Shareholder's Equity16382.4%166,3071,0099,675148,05223,6278,33828,19535,15138,54934,15838,88844,27747,55137,57512830,18031,46635,43741,548--
  Retained Earnings-4.5%-172,600-165,200-156,500-149,154-442,959-139,600-438,368-431,405-428,965-111,141-428,600-423,156-419,822-414,715-70,887-410,738-404,278-398,449-392,126-384,269-374,081
  Additional Paid-In Capital0.1%166,307166,218166,185148,052466,584147,586466,561466,554467,368145,160467,486467,287467,227452,174109,157440,917435,682433,826433,614423,750423,330
Shares Outstanding0.2%4,7884,7804,7732,6951,8162,8791,8161,8201,820-1,8201,8201,3991,049-------
Float--------11,864----71,183----39,995---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12023Q12022Q42022Q32022Q32022Q22022Q22022Q12022Q12021Q42021Q42021Q32021Q32021Q22021Q12020Q42020Q42020Q32020Q2
Cashflow From Operations18.5%-6,981-8,561-6,741-11,058-4,700-1,528-9,984-4,138-15,125--2,803-6,114-2,786--3,218-5,302-5,712
  Share Based Compensation169.7%89.0033.001,186--1,817-25.001,37523.0064326.00--1,3981,68960.00215236-184255210
Cashflow From Investing-----35.00--66.00--77.00--58.00--6.00--50.00156-210--327-63.00-120
Cashflow From Financing266.7%2,000-1,20021,201--1,468--1,000--98244.004,312-2,503--20,75011,136-4,877994-107

ADXS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenues from licensing agreement and others$ 91$ 13$ 587
Cost of services(91)(13)(497)
Gross profit90
Operating expenses:    
Research and development5,6837,19918,67120,282
General and administrative1,4482,8818,8157,586
Operating loss(7,131)(10,080)(27,486)(27,778)
Financial (loss) income, net(143)17241
Loss before income tax(7,274)(10,079)(27,414)(27,737)
Taxes on income(65)(106)4,015(509)
Net loss$ (7,339)$ (10,185)$ (23,399)$ (28,246)
Net Loss per share attributable to common stockholders, basic$ (1.53)$ (3.51)$ (5.03)$ (9.81)
Net loss per share, basic and diluted$ (1.53)$ (3.51)$ (5.03)$ (9.81)
Weighted average common shares outstanding, basic[1],[2]4,784,4742,901,4784,648,5992,879,465
Weighted average common shares outstanding, diluted[1],[2]4,784,4742,901,4784,648,5992,879,465
[1]Common Stock, additional paid-in capital and per share data have been retroactively adjusted for the impact of the January 2023 merger between Old Ayala, Inc. (f/k/a Ayala Pharmaceuticals, Inc.) and Ayala Pharmaceutical, Inc.(f/k/a Advaxis, Inc.). See note 1
[2]Exercise price and warrant numbers of Old Ayala’s warrants have been retroactively adjusted for the impact of the January 2023 Merger, see note 1

ADXS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 2,123$ 2,408
Short-term restricted bank deposits102110
Trade receivables234
Prepaid expenses and other current assets2,327436
Total current assets4,5523,188
LONG-TERM ASSETS:  
Deferred issuance costs1,953
Operating lease right of use asset1,2761,462
Intangible assets, net107
Property and equipment, net845960
Other assets201206
Total long-term assets2,4294,581
Total assets6,9817,769
CURRENT LIABILITIES:  
Trade payable5,0564,080
Operating lease liabilities480419
Accrued expenses1,556551
Accrued payroll and employee benefits1,231994
Other accounts payable204169
Total current liabilities8,5276,213
LONG TERM LIABILITIES:  
Long-term warrant liability65
Convertible Note2,068
Uncertain tax position1,6301,323
Long-term operating lease liabilities9321,332
Total long-term liabilities4,6952,655
STOCKHOLDERS’ EQUITY (DEFICIENCY):  
Common Stock of $0.001 par value per share; 170,000,000 and 37,480,000 shares authorized on September 30, 2023 (unaudited) and on December 31, 2022, respectively; 4,838,322 and 2,775,906 shares issued and on September 30, 2023 (unaudited) and December 31, 2022, respectively; 4,788,091 and 2,695,067 shares outstanding on September 30, 2023 (unaudited) and December 31, 2022, respectively.[1]53
Additional paid-in capital[1]166,307148,052
Accumulated deficit(172,553)(149,154)
Total stockholders’ equity (deficiency)(6,241)(1,099)
Total liabilities and stockholders’ equity (deficiency)$ 6,981$ 7,769
[1]Common Stock, additional paid-in capital and per share data have been retroactively adjusted for the impact of the January 2023 merger between Old Ayala, Inc. (f/k/a Ayala Pharmaceuticals, Inc.) and Ayala Pharmaceutical, Inc.(f/k/a Advaxis, Inc.). See note 1
ADXS
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.
0
 CEO
 WEBSITEwww.ayalapharma.com

Advaxis Inc Frequently Asked Questions


What is the ticker symbol for Advaxis Inc? What does ADXS stand for in stocks?

ADXS is the stock ticker symbol of Advaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Advaxis Inc (ADXS)?

As of Thu Feb 22 2024, market cap of Advaxis Inc is 9.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADXS stock?

You can check ADXS's fair value in chart for subscribers.

What is the fair value of ADXS stock?

You can check ADXS's fair value in chart for subscribers. The fair value of Advaxis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Advaxis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Advaxis Inc a good stock to buy?

The fair value guage provides a quick view whether ADXS is over valued or under valued. Whether Advaxis Inc is cheap or expensive depends on the assumptions which impact Advaxis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADXS.

What is Advaxis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ADXS's PE ratio (Price to Earnings) is -0.56 and Price to Sales (PS) ratio is 28.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Advaxis Inc's stock?

In the past 10 years, Advaxis Inc has provided -0.374 (multiply by 100 for percentage) rate of return.